Articles From: Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer to EXFO to Address Financial Community


Exelixis, Inc. (NASDAQ:EXEL) today announced positive top-line results from a randomized phase 2 trial of cabozantinib and erlotinib alone or in combination as second- or third-line therapy in patients with stage IV EGFR wild-type non-small cell lung cancer (NSCLC). This trial (Study E1512) is sponsored by the U.S. National Cancer Institute (NCI) through a Cooperative Research and Development Agreement between the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis, NCI and Exelixis.
Sign-up for Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced top-line results from the final analysis of COMET-2, a randomized, double-blind, controlled trial of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) who are suffering from moderate to severe pain despite optimized narcotic medication, and whose disease has progressed following treatment with docetaxel as well as abiraterone and/or enzalutamide.
Sign-up for Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With Metastatic Castration-Resistant Prostate Cancer investment picks
Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the third quarter of 2014 and provided an update on its progress toward delivering upon its key corporate objectives and clinical development milestones.
Sign-up for Exelixis Announces Third Quarter 2014 Financial Results and Provides Corporate Update investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced that the enrollment target of 650 patients has been reached for METEOR, the company’s phase 3 pivotal trial of cabozantinib in patients with metastatic renal cell carcinoma (RCC) who have experienced disease progression following treatment with at least one VEGFR tyrosine kinase inhibitor (TKI). Top-line efficacy and safety data from METEOR are now expected in the second quarter of 2015.
Sign-up for Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.
Sign-up for Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2 investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.
Sign-up for Exelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18 investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced its collaborator Genentech, a member of the Roche Group, has completed the filing of its New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib for previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation.
Sign-up for Exelixis’ Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and Vemurafenib for the Treatment of Patients With BRAF V600 Mutation-Positive Advanced Melanoma investment picks
Exelon Corporation (NYSE:EXC) and Pepco Holdings Inc. (NYSE:POM) today announced that they have reached a settlement in the proceeding before the New Jersey Board of Public Utilities (BPU) to review the two companies’ proposed merger, which was announced on April 30, 2014.
Sign-up for Exelon and Pepco Holdings Inc. Reach Settlement Agreement with New Jersey Board of Public Utilities Staff in Proposed Merger investment picks
Exelon Corporation (NYSE: EXC) announced third quarter 2014 consolidated earnings as follows: Third Quarter “Exelon achieved earnings above our guidance range this quarter, with strong performance from both our utility and generation businesses,” said Christopher M.
Sign-up for Exelon Announces Third Quarter 2014 Results investment picks
2014/12/1
Employee volunteers from across Exelon’s family of companies participated in more than 130 service projects in Illinois, Maryland and Pennsylvania to celebrate #GivingTuesday (December 2). Approximately 1,300 employees volunteered over 9,700 hours to projects in November, including sorting and wrapping toys for the holidays, mentoring students and packaging food for needy families at organizations in the communities Exelon serves.
Sign-up for Exelon Employees Celebrate #GivingTuesday by Volunteering at More Than 130 Community Service Events investment picks
2015/1/8
Exelon Generation announced that it has priced $750 million of Senior Notes maturing on Jan.
Sign-up for Exelon Generation Announces $750 Million Bond Sale investment picks
2015/1/6
WARRENVILLE, Ill.
Sign-up for Exelon Generation Promotes Top Two Nuclear Execs investment picks
2014/11/5
Emerging technologies from drone robotics to smart home devices were on display Tuesday at Exelon Corporation’s third Innovation Expo, an event aimed at bringing employees and outside experts together to explore how to apply creative solutions to complicated business challenges.
Sign-up for Exelon Hosts Innovation Expo Focused on the “Internet of Things” investment picks
2014/10/23
Exelon arranged $123 million in credit lines with 31 community and minority-owned banks in Illinois, Pennsylvania, Maryland and New Jersey, reinforcing the company’s commitment to invest in the diverse communities it serves.
Sign-up for Exelon Secures Credit Agreements with 31 Minority and Community Banks in Program’s Twelfth Year investment picks
2015/1/12
Exelon today issued the following statement on the State of Illinois report on potential nuclear power plant closings prepared in response to House Resolution 1146: We thank the state for its attention and work on such an important issue for Illinois and the future of the state’s energy assets.
Sign-up for Exelon Statement on Illinois Nuclear Power Plant Report investment picks
2014/11/13
As the energy industry undergoes rapid changes, Exelon is executing a strategy to grow and diversify the company through targeted investments in core markets and promising technologies with the potential to reshape the energy landscape, Exelon CEO Chris Crane told the 49th Annual EEI Financial Conference today.
Sign-up for Exelon’s Diversification Strategy Drives Growth in Challenging Energy Market investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0985200001&sourceType=1 http://www.ccnmatthews.com/logos/20090201-exlo.JPG VANCOUVER, BRITISH COLUMBIA --
Sign-up for Exeter Drilling Continues to Encounter Significant Water investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0985087002&sourceType=1 http://www.ccnmatthews.com/logos/20090201-exlo.JPG VANCOUVER, BRITISH COLUMBIA --
Sign-up for Exeter Files Amended Technical Report on Caspiche investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0978436001&sourceType=1 http://www.ccnmatthews.com/logos/20090201-exlo.JPG VANCOUVER, BRITISH COLUMBIA --
Sign-up for Exeter Resource Corporation : Detailed Metallurgical Testwork Confirms High Gold Recoveries on Caspiche Heap Leach Project investment picks
2015/1/13
QUEBEC CITY , Jan.
Sign-up for EXFO Announces Election of Directors investment picks
2015/1/13
EXFO Announces Election of Directors Canada NewsWire QUEBEC CITY , Jan.
Sign-up for EXFO Announces Election of Directors investment picks
2015/1/7
EXFO Announces Substantial Issuer Bid Canada NewsWire EXFO to repurchase up to C$30,000,000 of its subordinate voting shares QUEBEC CITY , Jan.
Sign-up for EXFO Announces Substantial Issuer Bid investment picks
2015/1/7
EXFO to repurchase up to C$30,000,000 of its subordinate voting shares QUEBEC CITY , Jan.
Sign-up for EXFO Announces Substantial Issuer Bid investment picks
2014/11/11
Extended multi-stage ODUmuxing and SONET/SDH client mappings now available on the FTB/IQS-85100G Packet Blazer series QUEBEC CITY, Nov.
Sign-up for EXFO Enhances 40G/100G lab testing capabilities to allow NEMs and carrier labs to fully qualify and test 100G network elements investment picks
This latest release to the all-in-one Ethernet/Optical FTB-700G Series and FTB-800 NetBlazer Series empowers field technicians to easily test and troubleshoot fiber-to-the-antenna (FTTA) networks.
Sign-up for EXFO Expands CPRI Offering to Support Next-generation Fibre-based Remote Radio Access Networks (RAN) investment picks
QUEBEC CITY , Nov.
Sign-up for EXFO joins effort to ensure Canada gets its share of $5 trillion high-tech pie investment picks
2014/12/10
EXFO's iOLM now features iCERT, an accurate and error-free fiber certification tool meeting the latest industry standards (including TIA and ISO). QUEBEC CITY, Dec.
Sign-up for EXFO Releases Intelligent and Automated Optical Cable Certifier for Data Centers investment picks
2015/1/7
EXFO Reports First-Quarter Results for Fiscal 2015 Canada NewsWire QUEBEC CITY , Jan.
Sign-up for EXFO Reports First-Quarter Results for Fiscal 2015 investment picks
2015/1/7
Sales reach US$56.7 million , up year-over-year from US$56.0 million Gross margin amounts to 62.6% of sales, up year-over-year from 62.2% Adjusted EBITDA totals US$3.2 million , up year-over-year from US$2.3 million QUEBEC CITY, Jan.
Sign-up for EXFO Reports First-Quarter Results for Fiscal 2015 investment picks
2014/12/10
QUEBEC CITY , Dec.
Sign-up for EXFO to Address Financial Community investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer to EXFO to Address Financial Community
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent